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1684-1182/Copyright ª 2014, Taiwan S
BY-NC-ND license (http://creativecomAminoglycoside resistance determinants among 188 aminoglycoside-resistant blood culture Es-
cherichia coli isolates from a tertiary hospital in Hong Kong, from 2004 to 2010 were investi-
gated. Overall, 91% had aac(3)-II, 12.2% had aac(60)-Ib/Ib-cr, and 5.4% had the methylase
genes (rmtB, armA). Aminoglycoside-resistant isolates with aac(0)-Ib/Ib-cr, rmtB, and armA
often had coresistance to multiple other antibiotics.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Escherichia coli is the most common cause of Gram-negative
bacteremia. For many years, a b-lactam in combination withInfectious Diseases, Depart-
Infection, The University of
fulam Road, Pokfulam, Hong
k (P.-L. Ho).
.08.012
ociety of Microbiology. Published
mons.org/licenses/by-nc-nd/4.0/an aminoglycoside has been the standard therapy for empir-
ical therapy suspected or confirmed Gram-negative bacter-
emia.1,2 Depending on the prevalence of resistance, the
preferred aminoglycoside in most geographic areas is either
gentamicin or amikacin.3 Genes encoding aminoglycoside-
modifying enzymes (AME) and 16S ribosomal RNA (rRNA)
methylases are the main causes of aminoglycoside resis-
tance.3,4 In Gram-negative bacteria, the main gentamicin-
resistant, AME genes are aac(30)-I, aac(30)-II, aac(30)-III,
aac(40)-IV, and ant(20 0)-I.3 Early epidemiological studies haveby Elsevier Taiwan LLC. This is an open access article under the CC
).
124 P.-L. Ho et al.shown that amikacin resistance often involved aac(60)-Ib and
occasionally aph(40)-II and aph(30)-VI.5 Because not all the
substrates for a given AME may be tested resistant at the
currently adopted breakpoints, interpretive reporting of
susceptibility results is widely practiced according to the
resistance profile of different aminoglycosides.6 Recent
studies have also highlighted the increasing occurrence of 16S
rRNA methylases, which cause high-level resistance [mini-
mum inhibitory concentration (MIC) 512 mg/mL] to all the 4-
,6-aminoglycosides.4 Therefore, there is a need to regularly
update theprevalent aminoglycoside resistancemechanisms.
Here, we investigated the occurrence and distribution of the




The isolates were recovered from blood cultures of patients
who were treated in a regional hospital in Hong Kong, Peo-
ple’s Republic of China. The hospital has 1400 acute care
beds and provides service for all the clinical disciplines. All
the isolates were stored in MicroBank (Pro-Lab Diagnostics,
Cheshire, United Kingdom) at 80oC until testing. Bacteria
were identified by the VITEK GNI system (bioMerieux, Hong
Kong). All the blood culture isolates that were viable during
2004e2010 were included. Only one isolate per patient was
included in this study. For those patients with more than one
isolate, only the first isolate was tested. A total of 188 iso-
lates of E. coli including 29 isolates from 2004 to 2008 and
159 isolates from 2009 to 2010 were included.
Antimicrobial susceptibility testing
The Clinical Laboratory Standards Institute’s disc diffusion
method was used for susceptibility testing: gentamicin
 15 mm (MIC  4 mg/mL) sensitive, 13e14 mm (MIC 8 mg/
mL) intermediate,  12 mm (MIC  16 mg/mL); and ami-
kacin 17 mm (MIC  16 mg/mL) sensitive, 15e16 mm (MIC
32 mg/mL) intermediate,  14 mm (MIC  64 mg/mL).2 The
double-disk approximation method was used for detection
of extended-spectrum b-lactamases (ESBL) as previously
described.7
Microbiological methods
Genes encoding AME [aac(3)-II, aac(60)-Ib/Ib-cr, ant(20 0)-Ia,
ant(40)-IIa, and aph(30)-VIa] and 16S rRNA methylases (rmtA,
rmtB, rmtC, rmtD, rmtE, and armA) were sought by poly-
merase chain reaction (PCR) using specific primers1,2,8 and
representative amplicons were sequenced for confirmation.
Samples positive for aac(60)-Ib were further analyzed by
digestion with BstF5I (Takara Bio Inc., Otsu, Japan) to
identify the aac(60)-Ib-cr variant, which lacks the BstF5I re-
striction site present in the wild-type gene.9 Among the ESBL
producers, genes related to the CTX-M subgroups (1, 2, 8, 9,
and 25) were identified by PCR.10 Multilocus sequence typing
(MLST) was carried out by the University of Warwick scheme
(http://mlst.warwick.ac.uk/mlst/).Statistical analysis
The Chi-square or Fisher’s exact test were used for statis-
tical analysis. A two-tailed p < 0.05 was considered sig-
nificant. All analyses were performed using statistical
software (SPSS, version 16.0; SPSS Inc., Chicago, IL, USA).Results
All 188 isolates were gentamicin-resistant (Gen-R), of which
19.7% (37/188) and 32.4% (61/188) had coresistance to ami-
kacin (Ak-R) and netilmicin, respectively. High-level resis-
tance, as indicated by the absence of an inhibition zone
around the discs, to gentamicin, amikacin, and netilmicin
were detected in 98.4% (185/188), 19.7% (37/188), and 8.0%
(15/188) of the isolates, respectively. Eleven isolates (5.9%)
exhibited high-level resistance for all three aminoglycosides.
The phenotypic and genotypic characteristics of the isolates
stratified by gentamicin and amikacin resistance patterns are
summarized in Table 1. The comparison showed that Gen-R/
Ak-R isolates were more likely than Gen-R/Ak-S isolates to be
ESBL positive, ciprofloxacin resistant, chloramphenicol
resistant, and multidrug resistant.
PCR showed that 95.2% of the isolates (179/188) were
positive for at least one aminoglycoside resistance gene:
153 isolates (81.4%) had one gene, 26 (13.8) had two
genes, and one (0.5%) had three genes. Overall, 171 iso-
lates (91%) had aac(3)-II, 23 (12.2%) had aac(60)-Ib/Ib-cr
(including 12 aac(60)-Ib and 11 aac(60)-Ib-cr), eight (4.3%)
had rmtB, four (2.1%) had ant(20 0)-Ia, and two (1.1%) had
armA. The prevalence of aac(3)-II gene among isolates
collected in 2004e2008 and 2009e2010 were 65.5% (19/29)
and 95.6% (152/159), respectively (p < 0.001). All 10 iso-
lates positive for rmtB or armA exhibited high-level
resistance to both gentamicin and amikacin with the iso-
lates growing to the edges of the discs. By comparison,
only three of the aac(60)-Ib/Ib-cr-positive isolates had no
inhibition zones around the amikacin disc. The remaining
aac(60)-Ib/Ib-cr-positive isolates (n Z 20) had amikacin
inhibition diameters that ranged from 9 mm to 23 mm,
including five isolates with inhibition diameters that fall
into the susceptible range (17e23 mm). The proportions of
ESBL producers among isolates positive or negative for the
16s rRNA methylase genes were similar [33.3% (3/9) vs.
33.0% (59/179), p Z 0.98]. By contrast, significantly more
aac(60)-Ib/Ib-cr-positive isolates than aac(60)-Ib/Ib-cr-
negative isolates were ESBL producers [69.6% (16/23) vs.
27.9% (46/165), p < 0.00]). CTX-M-type genes were
detected in 90.3% of the ESBL-producers (56/62): 46 iso-
lates had blaCTx-M-9G, eight had blaCTx-M-1G, and two had
both blaCTx-M-9G and blaCTx-M-1G. Six isolates were negative
for all blaCTx-M subgroup genes. MLST analysis revealed
that the 37 Gen-R/Ak-R isolates belong to 18 different
sequence types (STs). Six STs including ST405 (n Z 8),
ST131 (nZ 6), ST95 (nZ 4), ST38 (nZ 3), ST648 (nZ 2),
and ST354 (nZ 2) comprised 25 isolates. The remaining 12
STs had one isolate each (ST12, ST46, ST88, ST117, ST167,
ST173, ST224, ST393, ST453, ST964, ST1287, and ST2003).
The 10 isolates with the 16s rRNA methylase genes
belonged to seven STs (ST95, ST117, ST224, ST405, ST453,
ST964, and ST1287).
Table 1 Occurrence of AMG genes according to aminoglycoside resistance phenotypes
No. (%) of isolates Pb
Total Gen-R/Ak-S Gen-R/Ak-R
Number of isolates 188 151 37
Coresistance
ESBL 62 (33.0) 45 (29.8) 17 (45.9) 0.06
Cotrimoxazole 151 (80.3) 122 (80.8) 29 (78.4) 0.7
Ciprofloxacin 106 (56.4) 71 (47.0) 35 (94.6) < 0.001
fosfomycin 7 (3.7) 7 (4.6) 0 (0) 0.4
chloramphenicol 67 (35.6) 43 (28.5) 24 (64.9) < 0.001
MDR 68 (36.2) 44 (29.1) 24 (64.9) < 0.001
Aminoglycoside resistance genes
aac(3)-II 171 (91.0) 146 (96.7) 25 (67.6) < 0.001
ant(2”)-Ia 4 (2.1) 0 (0) 4 (10.8) 0.001
aac(6’)-Ib 11 (5.9) 1 (0.7) 10 (27.0) < 0.001
aac(6’)-Ib-cr 12 (6.4) 4 (2.6) 8 (21.6) < 0.001
rmtB 8 (4.3) 0 (0) 8 (21.6) < 0.001




None 8 (4.3) 5 (3.3) 3 (8.1)
1 153 (81.4) 141 (93.4) 12 (32.4)
2 or more 27 (14.4)a 5 (3.3) 22 (59.5)
a Including aac(3)-II þ aac(60)-Ib (nZ 9), aac(3)-II þ aac(60)-Ib-cr (nZ 8), aac(3)-II þ rmtB (nZ 5), aac(60)-Ib-cr þ ant(20 0)-Ia (nZ 3),
aac(60)-Ib þ ant(20 0)-Ia (n Z 1), aac(3)-II þ aac(60)-Ib-cr þ armA (n Z 1).
b For Gen-R/Ak-S versus Gen-R/Ak-R comparisons.
Ak-R Z amikacin-resistant; Ak-S Z amikacin-susceptible; Gen-R Z gentamicin-resistant; MDR Z multidrug resistant (as defined by c-
resistance involving three of more of ESBL, cotrimoxazole, ciprofloxacin, fosfomycin, and chloramphenicol).
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This study showed that a substantial proportion of the
gentamicin resistance in E. coli blood culture isolates was
attributed to aac(3)-II. In our region, the annual prevalence
of gentamicin and amikacin resistance among clinical iso-
lates of E. coli ranged 30e33% and 1e3%, respectively
during 2000e2010.7 We previously demonstrated that 84.1%
of gentamicin-resistant E. coli collected from patients with
urinary tract infection in 2002e2004 was positive for
aac(3)-II.2 Therefore, this AME gene has been the predom-
inant resistance determinant in different E. coli pop-
ulations for the past decade. This may be explained by the
fact that gentamicin is the workhorse aminoglycoside in
local clinical practices. The aac(3)-II gene has at least five
sequence alleles, from aac(3)-IIa to aac(3)-IIe.2,3 In China,
the prevalent alleles were aac(3)-IId and aac(3)-IIe,
whereas in other parts of the world the main alleles were
from aac(3)-IIa to aac(3)-IIc.2,3 The aac(3)-II produces
resistance to gentamicin, tobramycin, and netilmicin.3
Given its stronger affinity for gentamicin than tobramycin
and netilmicin, strains with aac(3)-II are highly resistant to
gentamicin but may only exhibit low-level resistance to the
latter two aminoglycosides.3 In the current collection,
71.3% of the aac(3)-II positive isolates (122/171) had
netilmicin inhibition zones larger than the CLSI breakpoint
(i.e.  15 mm inhibition zone, equivalent to MIC  8 mg/mL)
and would be classified as susceptible. In areas where
aac(3)-II are common, sensitive result for tobramycin andnetilmicin in gentamicin-resistant E. coli should be sup-
pressed or be reported with a caution statement.6
Among the amikacin-resistant isolates, one or more
resistance determinants (aac(60)-Ib/Ib-cr, rmtB, and armA)
were identified in 73.0% (27/37). The mechanism of ami-
kacin resistance in the remaining 10 isolates was unknown.
Our findings showed that the gentamicin and amikacin
coresistant isolates were genetically diverse, suggesting
that horizontal spread rather than expansion of clones are
playing more important roles in the dissemination of the
resistance determinants. Among E. coli isolates, previous
studies have highlighted the common occurrence of
aac(60)-Ib/Ib-cr, armA, or rmtB genes co-carried with
blaCTx-M on the same plasmids.
9 In addition, aac(60)-Ib/Ib-
cr, rmtB, and blaCTx-M could also occur as integron cas-
settes.9 Whether those genes are also carried on the same
plasmids in our isolates deserve further investigation in the
future. Our results demonstrated that most gentamicin
and amikacin coresistant E. coli were resistant to cipro-
floxacin. The association may be explained by the high
prevalence of aac(60)-Ib-cr among the gentamicin- and
amikacin-coresistant E. coli. Aac(60)-Ib-cr reduces the ac-
tivity of ciprofloxacin by acetylation, and presence of this
enzyme also increased the frequency of selection of
chromosomal mutants upon exposure to ciprofloxacin.9
In conclusion, this work shows the prevalence of aac(60)-
Ib-cr and rmtB among blood culture isolates with coresist-
ance to aminoglycosides and multiple other antibiotic
classes. Emerging multidrug resistance involving drugs
126 P.-L. Ho et al.considered to be critically important for serious human
infections highlight the need to expedite integration of
rapid diagnostic testing, such as matrix-assisted laser
desorption/ionization time-of-flight with antimicrobial
stewardship team intervention.
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